A Pilot Study of Preoperative Gefitinib for Early-Stage Lung Cancer to Assess Intratumor Drug Concentration and Pathways Mediating Primary Resistance

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella et al. · New England Journal of Medicine · 2004 · 11.5K citations

Medicine, Oncology, Pharmacology +16

<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

J. Guillermo Paez, Pasi A. Jänne, Jeffrey C. Lee et al. · Science · 2004 · 9.4K citations

Medicine, Molecular Genetics, Oncology +17

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu et al. · New England Journal of Medicine · 2005 · 5.5K citations · Full text

Medicine, Oncology, Pharmacology +15

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

William Pao, Vincent A. Miller, Maureen F. Zakowski et al. · Proceedings of the National Academy of Sciences · 2004 · 4.3K citations · Full text

Medicine, Molecular Genetics, Oncology +16

Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer

Mark G. Kris, Ronald B. Natale, Roy S. Herbst et al. · JAMA · 2003 · 2.5K citations

Medicine, Oncology, Pharmacology +17